SynthesisFrontiers in medicine2026
Machine learning models for identifying prediabetes: a systematic review of performance, validation, and implications for primary care.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Machine learning models have been proposed for identifying prediabetes, but their methodological quality, generalisability, and readiness for primary care implementation remain uncertain. Methods: We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review registered in PROSPERO (CRD420251029165). Eight databases were searched from inception to 1 April 2025, with PubMed, Embase, and Web of Science Core Collection updated through 1 August 2026. The primary review question focused on current/prevalent prediabetes identification; longitudinal/prognostic studies addressing future dysglycaemia were retained only as supplementary evidence and interpreted separately. Principal performance and implementation conclusions were restricted to current/prevalent identification. Two reviewers independently screened studies and extracted data. Risk of bias and applicability were assessed using Prediction Model Risk of Bias Assessment Tool (PROBAST). Findings were synthesised descriptively because of heterogeneity. Results: Twenty-six studies involving 435,647 participants were included. Of these, 23 studies constituted the primary evidence base for current/prevalent prediabetes identification, whereas three longitudinal/prognostic studies were retained as supplementary evidence and interpreted separately. Across all included evidence, 110 models were reported. Development or internal validation area under the receiver operating characteristic curves (AUCs) ranged from 0.49 to 0.9989 across heterogeneous modelling tasks; the highest value represented overall multiclass discrimination rather than a prediabetes-specific binary AUC. Independent external validation was reported in only one study (1/26, 3.8%), in which the area under the receiver operating characteristic curve (AUROC) for prediabetes decreased from 0.746 in internal evaluation to 0.590 and 0.523 in two external cohorts. Fourteen studies were judged to have a low overall risk of bias, whereas 12 studies (46.2%) were judged to have a high overall risk of bias. Calibration, clinical utility assessment, and subgroup fairness evaluation remained limited. Conclusion: Machine learning models show potential to support current/prevalent prediabetes identification in primary care, particularly when based on routinely collected variables. However, strong performance observed during model development or internal validation should not be interpreted as evidence of implementation readiness. Given the limited independent external validation and insufficient evidence regarding calibration, clinical utility, fairness, and real-world workflow integration, current evidence remains insufficient to support routine primary care implementation. These conclusions relate to current/prevalent prediabetes identification and should not be extrapolated to longitudinal/prognostic prediction of future prediabetes, impaired fasting glucose, or related dysglycaemic progression. Systematic Review Registration: PROSPERO CRD420251029165.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.